Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1973 2
1974 1
1983 1
1984 1
2006 1
2008 1
2009 4
2010 4
2011 3
2012 6
2013 6
2014 7
2015 9
2016 9
2017 13
2018 13
2019 11
2020 18
2021 30
2022 24
2023 27
2024 20

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

196 results

Results by year

Filters applied: . Clear all
Page 1
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma.
Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, Zimmer L, Gutzmer R, Satzger I, Loquai C, Grabbe S, Vokes N, Margolis CA, Conway J, He MX, Elmarakeby H, Dietlein F, Miao D, Tracy A, Gogas H, Goldinger SM, Utikal J, Blank CU, Rauschenberg R, von Bubnoff D, Krackhardt A, Weide B, Haferkamp S, Kiecker F, Izar B, Garraway L, Regev A, Flaherty K, Paschen A, Van Allen EM, Schadendorf D. Liu D, et al. Nat Med. 2019 Dec;25(12):1916-1927. doi: 10.1038/s41591-019-0654-5. Epub 2019 Dec 2. Nat Med. 2019. PMID: 31792460 Free PMC article.
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy.
Michel L, Helfrich I, Hendgen-Cotta UB, Mincu RI, Korste S, Mrotzek SM, Spomer A, Odersky A, Rischpler C, Herrmann K, Umutlu L, Coman C, Ahrends R, Sickmann A, Löffek S, Livingstone E, Ugurel S, Zimmer L, Gunzer M, Schadendorf D, Totzeck M, Rassaf T. Michel L, et al. Eur Heart J. 2022 Jan 31;43(4):316-329. doi: 10.1093/eurheartj/ehab430. Eur Heart J. 2022. PMID: 34389849
[Malignant melanoma].
Lodde G, Zimmer L, Livingstone E, Schadendorf D, Ugurel S. Lodde G, et al. Hautarzt. 2020 Jan;71(1):63-77. doi: 10.1007/s00105-019-04514-0. Hautarzt. 2020. PMID: 31773173 German.
[Malignant melanoma].
Lodde G, Zimmer L, Livingstone E, Schadendorf D, Ugurel S. Lodde G, et al. Pathologe. 2020 May;41(3):281-292. doi: 10.1007/s00292-020-00776-x. Pathologe. 2020. PMID: 32206873 German.
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, Brase JC, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt HC, Dick J, Engel DR, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke JM, Klose JM, Fendler WP, Thommen DS, Helfrich I, Schadendorf D, Roesch A. Váraljai R, et al. Nat Cancer. 2023 Sep;4(9):1292-1308. doi: 10.1038/s43018-023-00610-2. Epub 2023 Jul 31. Nat Cancer. 2023. PMID: 37525015 Free PMC article.
Congo calling.
Livingstone E. Livingstone E. Science. 2024 Oct 4;386(6717):16-19. doi: 10.1126/science.adt5481. Epub 2024 Oct 3. Science. 2024. PMID: 39361755
[Immunotherapy for malignant melanoma].
Zaremba A, Zimmer L, Griewank KG, Ugurel S, Roesch A, Schadendorf D, Livingstone E. Zaremba A, et al. Internist (Berl). 2020 Jul;61(7):669-675. doi: 10.1007/s00108-020-00812-1. Internist (Berl). 2020. PMID: 32462249 Review. German.
Hepatocyte mARC1 promotes fatty liver disease.
Lewis LC, Chen L, Hameed LS, Kitchen RR, Maroteau C, Nagarajan SR, Norlin J, Daly CE, Szczerbinska I, Hjuler ST, Patel R, Livingstone EJ, Durrant TN, Wondimu E, BasuRay S, Chandran A, Lee WH, Hu S, Gilboa B, Grandi ME, Toledo EM, Erikat AHA, Hodson L, Haynes WG, Pursell NW, Coppieters K, Fleckner J, Howson JMM, Andersen B, Ruby MA. Lewis LC, et al. JHEP Rep. 2023 Feb 3;5(5):100693. doi: 10.1016/j.jhepr.2023.100693. eCollection 2023 May. JHEP Rep. 2023. PMID: 37122688 Free PMC article.
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
Becker JC, Ugurel S, Leiter U, Meier F, Gutzmer R, Haferkamp S, Zimmer L, Livingstone E, Eigentler TK, Hauschild A, Kiecker F, Hassel JC, Mohr P, Fluck M, Thomas I, Garzarolli M, Grimmelmann I, Drexler K, Spillner AN, Eckhardt S, Schadendorf D; DeCOG. Becker JC, et al. Lancet. 2023 Sep 2;402(10404):798-808. doi: 10.1016/S0140-6736(23)00769-9. Epub 2023 Jul 11. Lancet. 2023. PMID: 37451295 Clinical Trial.
196 results